Both the endogenous (Mtv) and the exogenous form of mouse mammary tumor virus (MMTV) encode a superantigen (Sag) protein in their 3Ј long terminal repeats (1, 2, 6 ). Sag's bind major histocompatibility complex (MHC) class II molecules, and this complex interacts with T cells expressing specific T-cell-receptor V ␤ elements (20, 31) . Presentation of Sag's by antigen-presenting cells therefore leads to a strong T-cell immune response. B cells have been shown to be among the primary targets of infection by MMTV, and presentation leads to a cognate T-cell-B-cell interaction similar to that induced by classical antigens (14, 27) . Endogenous Sag's have been shown to be presented preferentially but not exclusively by B cells, and little is known about the roles of other cell types in the presentation of MMTV Sag's after infection (18, 19, 28, 30, 41) .
It is known that the initial MMTV infection is very inefficient (15) and that Sag's play an important role in establishing a productive MMTV infection (10, 16) . Infected B cells are induced to clonally expand and to differentiate as a result of interaction with Sag-responsive CD4 ϩ T cells. This mechanism allows amplification of the virus in the absence of reinfection (15) .
Due to the low infectivity of MMTV, it has been difficult to infect target cells in vivo and in vitro. For most older infection studies, very high doses of virus together with Polybrene had to be used to increase levels of infection (17, 23, 24, 38, 39) . A highly reproducible and sensitive infection assay would play a key role in the characterization of receptors important for MMTV infection as well as in the detailed analysis of the cellular requirements for MMTV infection and Sag responses. Here we describe a novel in vitro method which allows the investigation of the contributions of cell surface receptors to infection as well as the ability of different antigen-presenting cells to induce a Sag response after infection by MMTV.
MATERIALS AND METHODS
Mice. BALB/c and C57BL/6 mice were purchased from Harlan OLAC Ltd. (Bicester, United Kingdom). BALB.D2 (Mtv-7-congenic BALB/c) mice were originally provided by H. Festenstein (9) , London Hospital Medical College, and subsequently bred and maintained in the Ludwig Institute animal facility. All mice used were 6 to 10 weeks old.
Milk collection. Milk was aspirated from MMTV(SW)-infected BALB/c mothers after intraperitoneal injection of 0.2 U of oxytocin (Sandoz, Basel, Switzerland). Pooled milk samples were diluted 1:3 with phosphate-buffered saline (PBS) and centrifuged at 1,000 ϫ g for 10 min to skim and remove the cell pellet. The virus concentration was 10 11 to 10 12 particles/ml (14) . Aliquots were stored at Ϫ70°C. Upon subcutaneous injection of MMTV(SW) into the hind footpads of BALB/c mice, a preparation of milk diluted 30ϫ in PBS gave an increase from 10 to 30% of V ␤ 6 ϩ CD4 ϩ T cells in their draining popliteal lymph nodes after 6 days.
In vitro infection and hanging-drop culture. Cell suspensions were prepared from spleen in Dulbecco's modified Eagle's minimum essential medium supplemented with 10% fetal calf serum. Upon titrations of cells and virus dose, the best in vitro culture was established with 2. (37) . Polyclonal goat antigp52 sera (81S000141, 81S000154, 78S000095, and 78S000048; Quality Biotech) and polyclonal rabbit anti-recombinant envelope serum (27b) as well as the monoclonal MMTV-neutralizing antibodies VE7, 2B5, 141, and 149 (27a) were used in the blocking studies. Cultured cells were directly labeled with fluorescent antibodies and analyzed on a FACScan flow cytometer with Lysis II software (Becton Dickinson).
PCR. DNA (1 g) extracted from BALB/c splenocytes infected in vitro with MMTV(SW) was amplified by PCR. The primers used were oligonucleotides specific for Mtv-7 and MMTV(SW) orf genes and were TGGCAACCAGGGAC TTATAGG and AATGTTTCAAAAGGGATCGAAGC for the 5Ј and 3Ј regions, respectively. PCR conditions were as follows: 1 min at 57°C, 1 min at 72°C, and 1 min at 95°C for 40 cycles in PCR buffer containing 20 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM MgCl 2 , 0.01% gelatin, 2 mM deoxynucleoside triphosphate, 3 Ci of [␣-
32 P]dATP, and 0.5 U of Taq polymerase (Perkin-Elmer Cetus, Norwalk, Conn.) on a Biometra cycler. PCR products were boiled and size fractionated on a 6% denaturing acrylamide gel.
Assessment of cell division. A proliferation assay was performed on cultured BALB/c splenocytes infected with MMTV(SW). BrdU (250 g/ml) was added to the cultures 5 days after infection, and BrdU incorporation was measured by flow cytometry (fluorescence-activated cell sorter [FACS] analysis) 24 h later. Staining steps were as follows (27) : surface-stained cells were fixed and permeabilized by incubation in ice-cold 0.15 M NaCl-95% ethanol for 30 min on ice and then in PBS containing 1% paraformaldehyde and 0.01% Tween 20 for 30 min at room temperature and for 30 min on ice. DNA from fixed cells was digested in 0.15 M NaCl-4.2 mM MgCl-10 M HCl with 50 Kunitz U of DNase I (Pharmacia) per ml for 45 min at 37°C. Cells were finally stained with anti-BrdU monoclonal antibody and subjected to FACS analysis.
Isolation of B and dendritic cells. Ten BALB/c spleens were cut in small pieces and digested for 20 min at 37°C in 10 mg of collagenase D (Boehringer) in 10 ml. After being washed, cells were centrifuged in a 35% bovine serum albumin (A-2153; Sigma) gradient for 10 min at 9,000 ϫ g. Before being surface stained, cells were incubated for 10 min with anti-Fc␥II and III receptor to avoid any unspecific binding. The low-density fraction, of which 25 to 30% was N418 ϩ cells and 50% was B220 ϩ cells, was recovered at the interphase of the gradient, and dendritic cells were further purified through FACS analysis by gating out Mac-1 ϩ and B220
ϩ cells. The high-density fraction of the gradient was incubated for 90 min at 37°C to let most of the remaining macrophages and dendritic cells adhere. From these cells, B220
ϩ and CD4 ϩ /CD8 ϩ lymphocytes were sorted by FACS analysis to eliminate the last contaminating cells (1% of macrophages or dendritic cells). The sorted cell preparations had a purity of Ͼ98% for dendritic cells (Ͻ1% contaminating B cells), and undetectable levels of dendritic cell contamination were found in both B and T cells (see Fig. 3C ). Sorted populations were added as follows: 1.5 ϫ 10 6 B cells, 10 5 dendritic cells, and 10 6 B cells plus 5 ϫ 10 4 dendritic cells, with each population having 10 6 T cells. Inhibition of infection or Sag presentation. The polyclonal anti-env sera were either incubated for 30 min at 4°C with 1 l of MMTV(SW) and then added to the hanging-drop culture at the onset of the culture or added to the culture after 2 to 3 days of infection. The antibodies directed against B-or T-cell markers were incubated for 30 min at 4°C with the cells, which were then infected. To distinguish between effects on infection and effects on Sag presentation, BALB.D2 splenocytes were analyzed in parallel. All antibodies used were maintained at the concentrations indicated in the figures for the period of culture.
Mixed-lymphocyte reaction. Irradiated splenocytes (5 ϫ 10 5 , 1,000 rad) from C57BL/6 or BALB.D2 mice were mixed with 10 5 BALB/c lymph node cells. [ 3 H]thymidine (1.5 Ci/ml) was added to the mixed-lymphocyte reaction mixture on day 3, and thymidine incorporation was measured 18 h later. FACS analysis to measure percentages of Sag-reactive T cells was performed on day 5.
RESULTS AND DISCUSSION
Initially, MMTV infects very few target cells both in vitro and in vivo. Only the amplification of the infected B cells by Sag-specific T cells allows detection of infection in vivo by PCR. In order to establish an in vitro infection system, we cocultured antigen-presenting cells and T cells in the presence of MMTV either in a conventional culture system or by using the hanging-drop technique. The latter method takes advantage of aggregation of cells in a pseudoorgan at the liquid-air interface so that interactions between cells are favored. Comparison of these two methods (data not shown) revealed a better and more reproducible Sag response when the hangingdrop technique was used. Under those conditions, a maximal increase in the MMTV(SW)-reactive V ␤ 6 ϩ CD4 ϩ T-cell subset from 10% to approximately 30% was observed after 8 to 9 days of culture (Fig. 1) .
The Sag response was more efficient in splenocytes than in lymph node cells following exposure to infectious MMTV (data not shown). Since B lymphocytes but not T cells have been shown to be among the primary targets of MMTV (13, 16) , the Sag response may simply reflect the higher proportion of B cells in spleen than in lymph nodes at the start of the infection. We also tested whether the Sag response in culture could be improved by addition of the cytokine interleukin 2. A similar Sag response was observed with or without the addition of exogenous interleukin 2, indicating that endogenous production of this cytokine is sufficient for maximal T-cell proliferation (data not shown). Optimal results were obtained with 1 ϫ 10 6 to 3 ϫ 10 6 spleen cells per well of a Terasaki plate. After subcutaneous injection of adult mice with MMTV (SW), infected B cells can be detected only in their draining lymph nodes after day 2 to 3, even when highly sensitive methods such as PCR are used (15) . The number of infected B cells increases due to the Sag response over a period of 6 days, and cell division of infected B cells is needed to allow detection of the reverse-transcribed viral genome (1, (13) (14) (15) (16) . In parallel, there is a strong expansion of Sag-reactive V ␤ 6-specific T cells. We monitored these two parameters (infection and T-cell response) in the in vitro infection system. A similar kinetics of infection was observed in splenocytes infected in vitro, as in the draining lymph nodes after in vivo injection of MMTV(SW) (Fig. 1) . A PCR signal was monitored and indicated a peak at day 4 after infection (Fig. 1A) . As in the in vivo model, no infection was measurable during the first day, confirming the low rate of infection (Ͻ1/1,000 cells) in vivo (15) . After 4 days of culture, the percentage of B cells started to decrease due to preferential death (data not shown). On day 9, B lymphocytes represented only 20% of the total cells compared to 50 to 60% at the onset of culture.
To measure the T-cell response to MMTV(SW) Sag, we determined the percentage of V ␤ 6 ϩ CD4 ϩ T cells after in vitro infection (Fig. 1B) . V ␤ 6 ϩ CD4 ϩ T cells started to increase around day 5 and reached a maximum between days 8 and 9. As expected, there was a parallel compensatory decrease in the irrelevant V ␤ 14 ϩ CD4 ϩ T-cell subset (14) . By comparison with the in vivo kinetics, the in vitro Sag response was delayed by several days, but in both systems, V ␤ 6 ϩ T cells reached a similar percentage of approximately 30% of CD4 ϩ T cells. It is possible that the faster in vivo kinetics reflects an initial recruitment of Sag-reactive T cells from the periphery to the draining lymph node, which obviously cannot happen in vitro. Evidence for such a mechanism in vivo has recently been reported (25, 27) .
To distinguish between preferential survival and preferential proliferation of Sag-reactive T cells, we determined the percentage of cells undergoing cell division during the culture period. Between day 5 and day 6 of culture, over 25% of V ␤ 6 ϩ
CD4
ϩ T cells incorporated BrdU compared to less than 1% of V ␤ 6 Ϫ CD4 ϩ T cells (Fig. 2) . Moreover, no proliferation appeared in a control V ␤ 8.2 ϩ CD4 ϩ T-cell subset which does not react with MMTV(SW) Sag (data not shown). These results clearly show that in vitro, an efficient proliferation of Sagreactive T cells occurs upon MMTV(SW) stimulation.
One of the key requirements for Sag presentation is MHC class II expression. It has been shown that Mtv-7, the endogenous equivalent of MMTV(SW), is presented almost exclusively by B cells (30, 41) . Other cells expressing MHC class II molecules, such as macrophages and dendritic cells, are very inefficient in presenting endogenous Sag (5, 18, 19, 28) . However, Ardavin et al. have recently shown that Mtv Sag's are expressed on the surfaces of splenic and thymic dendritic cells and that deletion of endogenous Sag-reactive thymocytes occurs in vitro (4), but little is known about the contribution of these antigen-presenting cells to exogenous MMTV-mediated infection and Sag response. We therefore used our in vitro model to assess their potential roles in the presentation of MMTV(SW) orf. Highly purified populations of B cells and dendritic cells mixed with T cells were infected in vitro with MMTV(SW), and the Sag response was monitored after 8 days of culture (Fig. 3) .
When purified B cells were mixed with T cells and infected with MMTV(SW), a maximal Sag response was observed (Ͼ30% V ␤ 6 ϩ CD4 ϩ T cells), showing not only that B lymphocytes are required as target cells but also that they are sufficient by themselves to be infected and to expand Sag-reactive T cells in vitro (Fig. 3A) . In contrast, the Sag response induced by the purified dendritic cells was weak (14% V ␤ 6 ϩ CD4 ϩ T cells) though significant, arguing for infection of this population. Several reasons might explain this low competence of dendritic cells: (i) they lack a specific receptor molecule(s) for MMTV infection and therefore internalize the virions inefficiently by nonspecific pathways; (ii) once infected, they can only inefficiently present Sag; and (iii) they do not survive long enough in culture (especially in the absence of additional dendritic cellspecific growth factors) to have the crucial interaction with T cells. However, based on these data, it cannot be excluded that dendritic cells do play a role in the Sag response in vivo. Indeed, it is known that an encounter with antigen can cause stimulation of immature dendritic (Langerhans) cells, which can migrate from nonlymphoid organs (skin, for example) via afferent lymph or blood vessels to the T-cell-dependent areas of lymphoid organs. This mobilization is accompanied by the maturation of dendritic cells into professional antigen-presenting cells due, for example, to up-regulation of MHC and costimulatory molecules in response to cytokines such as granulocyte-macrophage colony-stimulating factor (36). Hence, it is possible that mature dendritic cells that have already migrated to the spleen and matured can no longer be infected by MMTV in vitro, even if they can actively stimulate T cells in a mixedlymphocyte reaction and present protein antigens to sensitized T cells (7) . To exclude a defective stimulatory function of purified dendritic cells due to the isolation procedures used in this study, the same preparations of cells were shown to be efficient presenters in a mixed-lymphocyte reaction (Fig. 3B) . Macrophages purified from spleen were unable to survive for the 8-day culture period after MMTV infection in three independent experiments.
Since MMTV particles are thought to bind a cellular surface receptor via envelope proteins, antibodies against the viral envelope were used to test this assumption. Clearly, polyclonal anti-env sera inhibited the Sag response in the in vitro infection system in a dose-dependent fashion (Fig. 4A) . Interestingly, none of these antibodies blocked the Sag response when they were added 3 days after the onset of infection (Fig. 4B) , suggesting no significant role for env in the presentation of MMTV Sag. BALB.D2 mice express an endogenous form of MMTV(SW), Mtv-7, in all B cells (14) , whereas with addition of MMTV(SW), only the newly infected B cells can present Sag. To distinguish between antibody blocking at the level of infection and that at Sag presentation, we compared the effects of antibodies on T-cell activation by BALB.D2 splenocytes and after addition of MMTV(SW) (Fig. 4) . Neither polyclonal nor monoclonal anti-envelope antibodies blocked the response to endogenous Mtv-7 (not shown). To exclude the possibility that the inhibitory effects of these sera were due to intrinsic toxicity, we analyzed them in a mixed-lymphocyte reaction. The same level of thymidine incorporation was detected with all dilutions tested (Fig. 4C) . Three additional polyclonal sera and four monoclonal antibodies were tested in this system and yielded similar results (see Materials and Methods). Considered together, our data suggest that the action of these anti-envelope sera was virus neutralization, indicating that envelope proteins are required for infection but that they are not necessary for the Sag-dependent phase of the response. These results are in contradiction to the recent observations (11) that anti-envelope sera can inhibit the response to Sag presented by MMTV transgenic B cells. One of the sera utilized in our study was from the same source and from the same animal as the one used by Golovkina et al. (11) . It remains possible that antienvelope sera are able to inhibit very weak Sag responses.
Another important field of investigation which may lead to a With the new in vitro infection strategy, we can now address this problem directly by using B-cell-specific monoclonal antibodies. We therefore evaluated the roles of different surface molecules which might be implicated either in infection, Sag presentation, or B-cell-T-cell interaction. LFA-1 is considered to be a key molecule in B-cell-T-cell interaction. It is therefore not surprising that blocking its interaction with its ligand suppressed the Sag responses to both infectious (Fig. 4D) and endogenous virus (Fig. 4E) . A similarly crucial role in B-cell-T-cell collaboration was shown for the CD4 molecule. Using antibodies directed against MHC class II I-E or I-A molecules or both, we could also block the Sag responses to both MMTV(SW) and Mtv-7 in the following ways: completely with anti-IE/IA, very efficiently with anti-IE, and marginally with anti-IA. These results confirm the important role of MHC class II I-E molecules for presentation of Sag from either an endogenous or an exogenous origin (8, 12, 40) and suggest that I-A molecules do not contribute substantially to Sag presentation. All antibodies mentioned above were titrated from 30 to 1 g/ml, and 50% inhibition was measured after MMTV(SW) infection or incubation with BALB.D2 splenocytes at 2 to 3 and 3 to 4 g/ml of anti-IE/IA and anti-IE, respectively (data not shown). On the contrary, control antibodies anti-K d and L d and T-cell receptor V ␤ 10 were unable to block the Sag response even at the highest dose of 30 g/ml (data not shown). With anti-CD4 and anti-LFA-1, 80% inhibition was achieved at 1 g/ml.
Potential MMTV receptor candidates were tested in this in vitro infection assay, and all were found to have no effect on the infection. Some of these antibodies induce modulation of the surface molecules and can therefore inhibit infection even if they do not directly compete for virus binding. The following antibodies were found to have no effect on virus infection: anti-complement receptors 1 and 2 (clones 7G6 and 8C12, respectively), anti-CD80 and anti-CD86 (CTLA-4-Ig), anti-B220 (RA3-3A1), and anti-CD16/32 (2.4.G2). In summary, we have established an in vitro MMTV infection system which mimics the in vivo situation in terms of dose response, kinetics of infection, types of cells infected, and the resulting Sag response. The use of this approach will be key to the characterization of MMTV receptors.
